Q702 for the Treatment of Patients With Hematologic Malignancies

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
Mayo Clinic
Study ID
NCT06712810
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Hematopoietic and Lymphatic System Neoplasm
  • Histiocytic Sarcoma
  • Malignant Histiocytosis
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Primary Central Nervous System Lymphoma
  • Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
  • Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Recurrent Chronic Lymphocytic Leukemia
  • Recurrent Chronic Myelomonocytic Leukemia
  • Recurrent Erdheim-Chester Disease
  • Recurrent Fibroblastic Reticular Cell Sarcoma
  • Recurrent Follicular Lymphoma
  • Recurrent Histiocytic Sarcoma
  • Recurrent Interdigitating Dendritic Cell Sarcoma
  • Recurrent Langerhans Cell Histiocytosis
  • Recurrent Lymphoplasmacytic Lymphoma
  • Recurrent Myelodysplastic Syndrome
  • Recurrent Myelofibrosis
  • Recurrent Rosai-Dorfman-Destombes Disease
  • Recurrent Small Lymphocytic Lymphoma
  • Recurrent Waldenstrom Macroglobulinemia
  • Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Refractory Chronic Lymphocytic Leukemia
  • Refractory Chronic Myelomonocytic Leukemia
  • Refractory Erdheim-Chester Disease
  • Refractory Fibroblastic Reticular Cell Sarcoma
  • Refractory Follicular Lymphoma
  • Refractory Histiocytic Sarcoma
  • Refractory Interdigitating Dendritic Cell Sarcoma
  • Refractory Langerhans Cell Histiocytosis
  • Refractory Lymphoplasmacytic Lymphoma
  • Refractory Myelodysplastic Syndrome
  • Refractory Myelofibrosis
  • Refractory Rosai-Dorfman-Destombes Disease
  • Refractory Small Lymphocytic Lymphoma
  • Refractory Waldenstrom Macroglobulinemia
  • Rosai-Dorfman-Destombes Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Axl/Mer/CSF1R Inhibitor Q702 — DRUG
    Given PO
  • Biospecimen Collection — PROCEDURE
    Undergo blood and urine sample collection
  • Bone Marrow Aspiration — PROCEDURE
    Undergo bone marrow biopsy and aspiration
  • Bone Marrow Biopsy — PROCEDURE
    Undergo bone marrow biopsy and aspiration
  • Computed Tomography — PROCEDURE
    Undergo CT scan
  • Magnetic Resonance Imaging — PROCEDURE
    Undergo MRI
  • Positron Emission Tomography — PROCEDURE
    Undergo PET scan
  • Survey Administration — OTHER
    Ancillary study

Study Details

This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.

Key Dates

Start date
Aug 27, 2025
Status verified
Oct 2025
Primary completion
Sep 15, 2030
Completion
Sep 15, 2030

Study Design

Enrollment
46 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (Q702)
    Patients receive Q702 PO QD on days 1-7 and 15-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 6 cycles, patients who have not progressed/relapsed may continue on therapy at their current dose at MD/patient discretion for an additional 6 cycles. Patients undergo blood and urine sample collection and may undergo PET scan/CT scan or MRI and bone marrow aspiration and biopsy throughout the study.

Primary Outcome Measure

Incidence of dose limiting toxicity [ Time Frame: Up to 3 years ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Mayo Clinic in ArizonaScottsdaleArizona85259
Clinical Trials Referral Office
[email protected]
855-776-0015
Talal Hilal, MD (PRINCIPAL_INVESTIGATOR)
Mayo Clinic in RochesterRochesterMinnesota55905
Clinical Trials Referral Office
[email protected]
855-776-0015
Jithma P. Abeykoon, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Scottsdale, AZ

By research site
Mayo Clinic in Arizona· Scottsdale, AZMayo Clinic in Rochester· Rochester, MN

Related Studies